• Achieved higher end of FY26 Revenue and EBITDA guidance
• Total Revenue of $88.1m, up 33% YoY
• EBITDA of $27.2m, up 68% YoY
• Strong balance sheet with $25.9m cash and $140m undrawn debt
• 11.3 million samples processed during FY26, up 67% on FY25

Chrysos Corporation Ltd reported its full-year results for FY26, achieving the higher end of its guidance. Total revenue increased by 33% to $88.1 million, driven by the continued adoption of PhotonAssayTM technology and strong utilisation. EBITDA grew by 68% to $27.2 million, with an improved EBITDA margin of 31% compared to 24% in FY25. The company processed 11.3 million samples, a 67% increase from FY25. The balance sheet remains strong with $25.9 million in cash and $140 million in undrawn debt, providing ample funding for future growth. The company deployed seven units in FY26 and signed 24 new lease agreements, bringing the total contracted units to 87.

FY27 Revenue guidance: $100m - $120m

Chrysos Corporation Ltd expects continued growth in FY27, driven by the global adoption of PhotonAssayTM technology and increasing industry activity. The company plans to deploy additional units and expand its global footprint.